About us
- >
- About us >
- Information >
- Announcement
Announcement
-
2023-02-10Patent for "Compound Activating AMPK and Uses Thereof" aimed at treating inflammatory diseases has been approved in Canada.
-
2023-01-09ENERGI-F703EB has received a certification letter from the Office of Orphan Products Development (OOPD) of the US Food and Drug Administration (FDA),
-
2022-12-26ENERGI-F703EB has received a certification letter from the Office of Orphan Products Development (OOPD) of the US Food and Drug Administration (FDA),
-
2022-11-14In response to Energenesis Biomedical's application for listing, it is necessary for us to engage a certified public accountant to issue an inter
-
2022-10-28We has signed a new drug formulation development contract with CBC Biotechnological & Pharmaceutical Co., Ltd.
-
2022-10-18The Phase III clinical trial of ENERGI-F703 diabetic foot ulcer topical gel, which was applied for in the US, has successfully completed the 30-day re
-
2022-09-19Applied to the US FDA for an Investigational New Drug (IND) application for the Phase III clinical trial of ENERGI-F703 diabetic foot ulcer topical ge
-
2022-07-25Energenesis Biomedical has obtained US patent for developing AMPK activation technology for the treatment of human inflammatory diseases.
-
2022-07-11The clinical Phase II trial results of our company's novel diabetic foot ulcer healing drug (ENERGI-F703 GEL) have been published in the internat
-
2022-03-01"Compound for Activating AMPK and Its Use" has been approved for a Malaysian invention patent.